A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Potassium cation
Eltoprazine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Eltoprazine.
Potassium cation
Benperidol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Benperidol.
Potassium cation
Tandospirone
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Tandospirone.
Potassium cation
TD-8954
The risk or severity of adverse effects can be increased when Cannabidiol is combined with TD-8954.
Potassium cation
Perazine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Perazine.
Potassium cation
Ritanserin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ritanserin.
Potassium cation
Urapidil
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Urapidil.
Potassium cation
Indiplon
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Indiplon.
Potassium cation
AZD-3043
The risk or severity of adverse effects can be increased when Cannabidiol is combined with AZD-3043.
Potassium cation
Benzodiazepine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Benzodiazepine.
Potassium cation
Raclopride
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Raclopride.
Potassium cation
Piritramide
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Piritramide.
Potassium cation
Ketanserin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ketanserin.
Potassium cation
Orvepitant
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Orvepitant.
Potassium cation
Bromperidol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Bromperidol.
Potassium cation
Esreboxetine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Esreboxetine.
Potassium cation
Piclozotan
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Piclozotan.
Potassium cation
Carisbamate
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Carisbamate.
Potassium cation
Salvinorin A
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Salvinorin A.
Potassium cation
Eltanolone
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Eltanolone.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3